ZACROS Corporation, announce the investment of 49.98 million yen in the biotech startup Revorf Co., Ltd. (hereinafter referred to as “Revorf”) through a third-party allocation of shares on October 30, in order to accelerate the expansion of its medium- to long-term growing project of cell culture contract manufacturing business. Through this capital and business alliance, ZACROS will develop an efficient manufacturing process for neoself antigen-expressing cells, utilized by Revorf for its testing method, and undertake their commercial production.
■Overview of the Investee Company
（１）Company Name: Revorf Co., Ltd.
（２）Location: 2-1-17 Nihonbashi, Chuo-ku, Tokyo
（３）Established: November 2019
（４）Representative: Shinichi Sueda (CEO)
（５）Business Description: Development of diagnostic and therapeutic agents for autoimmune diseases
Development of diagnostic and therapeutic agents for infectious diseases
（６）URL：https://www.revorf.jp/
This strategic partnership will create synergies leveraging the strengths of both companies, therefore contributing to the advancement of medical technology.
Please refer to the news release for more details.